ERCP: Definition, Uses, and Clinical Overview

Posted on February 27, 2026 | by drcancer

ERCP Introduction (What it is)

ERCP is a procedure that combines endoscopy and X-ray imaging.
It is used to examine and treat problems in the bile ducts and pancreatic duct.
ERCP is commonly performed in hospitals or endoscopy centers by gastroenterology teams.
In oncology care, it is often used to evaluate or relieve blockage caused by tumors.

Why ERCP used (Purpose / benefits)

ERCP (endoscopic retrograde cholangiopancreatography) helps clinicians diagnose and manage conditions affecting the biliary system (the ducts that carry bile from the liver and gallbladder) and the pancreatic duct (the channel that drains the pancreas). These ducts sit near the pancreas, liver, gallbladder, and small intestine—organs frequently involved in abdominal cancers and cancer-related complications.

In cancer care, ERCP is most often used for two broad goals:

Diagnostic support: ERCP can help clarify the cause of bile duct or pancreatic duct narrowing (called a stricture). During ERCP, clinicians may collect samples (for example, brushings or biopsies) to look for cancer cells. This can support diagnosis when imaging suggests a blockage but the cause remains uncertain.
Therapeutic relief: Many cancers can compress or invade ducts, causing obstructive jaundice (yellowing of skin/eyes due to bile flow blockage), itching, infection risk, abnormal liver tests, and problems tolerating systemic therapy. ERCP can place a stent (a small tube) to reopen the duct and improve drainage.

Common oncology-related benefits include:

Symptom relief, especially from jaundice, itching, nausea, poor appetite, and fatigue related to bile duct obstruction.
Supportive care that can help patients proceed with planned cancer treatments when liver function is affected by blockage.
Infection management, when used to treat or prevent cholangitis (infection in the bile ducts) by restoring flow.
Targeted problem-solving in complex anatomy of the bile and pancreatic ducts, complementing CT, MRI/MRCP, and endoscopic ultrasound (EUS).

ERCP is not a “cancer treatment” in the way chemotherapy, radiation therapy, or surgery are, but it can be an important part of cancer-associated complication management and treatment planning. How and when it is used varies by cancer type and stage, and by clinician and case.

Indications (When oncology clinicians use it)

Oncology and gastroenterology teams commonly consider ERCP in situations such as:

New or worsening obstructive jaundice with imaging suggesting bile duct blockage
Suspected malignant biliary stricture, such as from pancreatic cancer, cholangiocarcinoma, ampullary cancer, gallbladder cancer, or metastatic disease compressing ducts
Need for biliary stent placement to restore drainage before or during systemic therapy (timing varies by clinician and case)
Cholangitis (bile duct infection) in the setting of obstruction, where drainage is part of management
Suspected pancreatic duct obstruction or leakage in selected cases (less common in routine oncology care than biliary indications)
Need for tissue sampling (brush cytology, biopsy) when other methods have not been diagnostic
Evaluation of post-surgical anatomy and complications (for example, after pancreatic or biliary surgery), in centers with relevant expertise
Management of stent-related issues, such as blockage or migration, in patients previously treated with stents

Contraindications / when it’s NOT ideal

ERCP is not appropriate for every patient or every duct problem. Situations where ERCP may be avoided, delayed, or replaced by another approach include:

Unstable medical condition where sedation/anesthesia risk outweighs benefit (decision varies by clinician and case)
Uncorrected bleeding risk, such as significant coagulopathy or low platelets, especially if an intervention like sphincterotomy is anticipated
Active acute pancreatitis in which ERCP is not expected to provide a clear benefit (exceptions can exist in specific obstructive scenarios)
Known or suspected gastrointestinal perforation, where endoscopy could worsen the injury
Severe contrast allergy (because ERCP commonly uses contrast dye under fluoroscopy), when alternatives are feasible
Anatomy that limits access to the papilla (the duct opening in the duodenum), such as after certain gastric or intestinal surgeries, unless specialized techniques are available
When noninvasive imaging is sufficient, such as when MRCP or CT already answers the diagnostic question and no duct therapy is needed
When another drainage route is preferable, such as percutaneous transhepatic biliary drainage (PTBD) or EUS-guided biliary drainage, depending on anatomy, urgency, and local expertise

How it works (Mechanism / physiology)

ERCP works through a combined endoscopic and radiologic pathway:

An endoscope (a flexible camera) is passed through the mouth into the stomach and then the duodenum (the first part of the small intestine).
The clinician identifies the major duodenal papilla, where the bile duct and pancreatic duct empty into the intestine.
A small catheter is used to cannulate (enter) the duct opening. Contrast dye is injected, and fluoroscopy (real-time X-ray) outlines the ducts.
If a narrowing or blockage is found, ERCP can be used therapeutically by:
Placing a stent to keep the duct open
Performing a sphincterotomy (a small cut to enlarge the opening) in selected situations
Taking brushings or biopsies for cytology/pathology
Dilating a stricture or clearing obstructing material when appropriate (the specific cause and strategy vary)

From an organ-system perspective, ERCP focuses on the hepatobiliary and pancreatic ducts. In oncology, strictures may be caused by tumor growth within the duct, tumor compression from outside the duct, treatment-related scarring, or a combination.

Concepts like “onset,” “duration,” and “reversibility” apply differently to ERCP than to medications:

Diagnostic information is immediate once imaging and sampling are completed, but final pathology results take additional time.
Therapeutic effects (such as bile flow improvement after stenting) may occur quickly, but durability varies by stent type, tumor behavior, infection risk, and ongoing cancer treatment.
ERCP interventions are generally reversible or repeatable in the sense that stents can be exchanged or removed, and follow-up procedures may be performed if problems recur.

ERCP Procedure overview (How it’s applied)

A simplified, general ERCP workflow in oncology care often follows this sequence. Specific steps vary by clinician and case.

Evaluation / exam
Symptoms and signs may include jaundice, itching, dark urine, pale stools, fever, abdominal pain, or abnormal liver tests. Clinicians review medical history, medications (including blood thinners), and prior surgeries that affect anatomy.
Imaging / biopsy / labs
Blood tests commonly include liver function tests and markers of infection. Imaging may include ultrasound, CT, MRI/MRCP, and/or EUS to define the level and cause of obstruction and to plan the approach.
Staging context (when relevant)
ERCP does not stage cancer by itself, but it can support staging and treatment planning by clarifying duct involvement and enabling tissue sampling. Overall staging depends on imaging, pathology, and clinical evaluation.
Treatment planning
The care team decides whether ERCP is intended to be primarily diagnostic (sampling) or therapeutic (drainage), and whether it is urgent (for example, suspected cholangitis). Sedation or anesthesia planning is part of this phase.
Intervention / therapy (the ERCP itself)
The endoscope is advanced to the duodenum, ducts are evaluated with contrast under fluoroscopy, and planned interventions are performed (such as stent placement or sampling).
Response assessment
Response is often assessed through symptoms (improvement in jaundice-related issues), lab trends (bilirubin and liver enzymes), and follow-up imaging when needed. Pathology results from sampling may guide next diagnostic steps.
Follow-up / survivorship support
Follow-up depends on the reason for ERCP. In cancer care, this may include monitoring stent function, planning systemic therapy, managing nutrition and symptoms, and coordinating care among oncology, gastroenterology, surgery, and palliative/supportive care teams.

Types / variations

ERCP can be adapted to different clinical goals and settings. Common variations include:

Diagnostic ERCP vs therapeutic ERCP
Diagnostic: focused on imaging the ducts and obtaining tissue samples.
Therapeutic: focused on restoring or improving duct drainage (for example, stenting).
Biliary ERCP vs pancreatic ERCP
Biliary ERCP is more common in oncology because malignant obstruction frequently affects bile flow.
Pancreatic duct interventions may be considered in selected situations, depending on anatomy and symptoms.
Stent types
Plastic stents: often used in shorter-term scenarios or when frequent exchanges are anticipated.
Metal stents (self-expanding): often considered when longer patency is desired; selection depends on treatment intent and anatomy. The choice varies by clinician and case.
ERCP with additional visualization
ERCP may be paired with techniques that allow direct visualization inside ducts (for example, cholangioscopy) in specialized centers, particularly when diagnosis remains unclear.
Altered anatomy ERCP
After certain surgeries (for example, gastric bypass or biliary reconstruction), standard access may be difficult. Specialized endoscopes or alternate approaches may be used depending on local expertise.
Inpatient vs outpatient ERCP
Outpatient ERCP is common for planned evaluation or stent exchange.
Inpatient ERCP may be used for urgent scenarios such as infection or severe obstruction.
Adult vs pediatric settings
Pediatric ERCP exists but is typically limited to specialized centers and indications differ from adult oncology practice.

Pros and cons

Pros:

Can be both diagnostic and therapeutic in a single procedure
Provides direct duct evaluation using contrast imaging under fluoroscopy
Enables biliary decompression with stenting for cancer-related obstruction
Allows tissue sampling (brushings/biopsy) in selected strictures
May improve symptoms and liver test abnormalities related to blockage
Often complements other tools (CT, MRCP, EUS) in a coordinated plan

Cons:

Carries procedure risks, including post-ERCP pancreatitis
Potential for infection (including cholangitis), bleeding, or perforation
May require repeat procedures, especially if stents clog or migrate
Tissue sampling can be nondiagnostic in some strictures, requiring additional testing
Involves sedation/anesthesia, which may be higher risk in frail patients
Uses fluoroscopy and contrast, which may not be ideal for everyone

Aftercare & longevity

Aftercare following ERCP typically focuses on monitoring for complications, confirming that the intended goal (diagnosis and/or drainage) was achieved, and coordinating next steps in the broader cancer-care plan.

General themes that influence outcomes and “longevity” of benefit include:

Cancer type and stage: The pattern of duct obstruction and likelihood of recurrence can vary by cancer type and stage.
Tumor biology and growth pattern: Some tumors cause progressive compression or intraductal growth, which can affect how long a stent remains effective.
Type of intervention performed: Stent type, stent position, and whether additional procedures were needed can influence how long drainage remains adequate.
Infection risk and biliary colonization: Bile duct obstruction can increase infection risk; episodes of cholangitis can affect clinical stability and treatment timing.
Systemic therapy plans: Chemotherapy, targeted therapy, or immunotherapy may depend on liver function; restoring bile flow can be part of enabling planned treatment, but responses vary by clinician and case.
Coexisting conditions: Liver disease, pancreatic disease, anticoagulation needs, and cardiopulmonary conditions can affect recovery and follow-up planning.
Follow-up coordination: Monitoring symptoms, liver tests, and stent function is often shared among oncology, gastroenterology, and primary care/supportive care teams. Access to timely follow-up can affect outcomes.

In survivorship or longer-term cancer control settings, ERCP may be used for stent exchanges or evaluation of new symptoms. In advanced cancer settings, ERCP is often part of supportive care focused on comfort and function, while recognizing that needs can change over time.

Alternatives / comparisons

ERCP is one option among several ways to evaluate or manage biliary and pancreatic duct problems. The best fit depends on the clinical question (diagnosis vs drainage), urgency, anatomy, and local expertise.

Common alternatives and comparisons include:

MRCP (magnetic resonance cholangiopancreatography)
A noninvasive MRI-based method that images bile and pancreatic ducts without endoscopy. MRCP is useful for diagnosis and mapping anatomy, but it cannot place a stent or directly treat an obstruction.
EUS (endoscopic ultrasound)
Uses ultrasound from inside the GI tract to visualize the pancreas, bile duct, and nearby lymph nodes. EUS is frequently used for biopsy (FNA/FNB) of masses or lymph nodes and can sometimes guide drainage procedures in experienced centers.
Percutaneous transhepatic cholangiography/drainage (PTC/PTBD)
A radiology-guided approach that accesses the bile ducts through the skin and liver. It can provide drainage when ERCP is not feasible or has failed, but it may involve external drains depending on the technique.
EUS-guided biliary drainage
An endoscopic alternative in specialized centers, often considered when ERCP cannot achieve drainage due to anatomy or tumor obstruction.
Surgery (bypass or resection)
For some patients, surgical procedures can bypass obstruction or remove the tumor.
Compared with ERCP, surgery is generally more invasive and depends on resectability, fitness for surgery, and overall cancer plan.
Systemic therapy and/or radiation therapy These treatments may shrink or control tumors contributing to obstruction, but they often do not provide the immediate mechanical relief that stenting can. In practice, duct drainage and cancer-directed therapy are sometimes used together, depending on goals of care.
Observation / active surveillance If a narrowing is mild, symptoms are minimal, and labs are stable, clinicians may choose close monitoring rather than immediate intervention. This decision varies by clinician and case.
Clinical trials In selected situations, trials may evaluate new stent designs, imaging strategies, or combined approaches. Eligibility and appropriateness vary by cancer type and stage.

ERCP Common questions (FAQ)

Q: Is ERCP painful?
ERCP is usually performed with sedation or anesthesia, so many patients do not feel pain during the procedure. Afterward, some people experience a sore throat, bloating, or mild abdominal discomfort. More significant pain can occur if a complication develops, which is why monitoring is important.

Q: What kind of anesthesia is used for ERCP?
Sedation ranges from moderate sedation to deep sedation or general anesthesia, depending on patient factors, procedure complexity, and facility practice. The anesthesia plan is typically chosen to support comfort and safety. The specific approach varies by clinician and case.

Q: How long does ERCP take and how long is recovery?
Procedure time and recovery time vary based on whether ERCP is diagnostic only or includes interventions like stenting or biopsy. Many patients are observed after the procedure to ensure they are stable and able to go home when appropriate. If ERCP is done urgently or complications are suspected, hospitalization may be needed.

Q: How safe is ERCP?
ERCP is widely used and often helpful, but it is not risk-free. Risks can include pancreatitis, bleeding, infection, perforation, and sedation-related complications. Clinicians weigh these risks against the potential benefits of diagnosis or drainage.

Q: What side effects or complications should people know about?
Common short-term effects can include sore throat, gas, and temporary discomfort. Clinically important complications may include pancreatitis, cholangitis, bleeding (especially if sphincterotomy is performed), or stent problems such as blockage or migration. Which risks matter most depends on the planned interventions and the patient’s overall health.

Q: Will ERCP cure my cancer or remove the tumor?
ERCP is generally not a cancer-curing procedure. In oncology, it is most often used to manage duct obstruction, obtain diagnostic samples, or relieve symptoms. Cancer control typically relies on surgery, systemic therapy, radiation therapy, or combinations of these, depending on the diagnosis and stage.

Q: What is the cost range for ERCP?
Costs vary widely based on country, hospital vs outpatient setting, insurance coverage, anesthesia type, and whether interventions like stenting or biopsy are performed. Additional costs may come from pathology testing, imaging, or hospitalization. Billing departments can usually explain how charges are structured.

Q: Can I return to work or normal activities after ERCP?
Many patients need a recovery period after sedation and may feel tired the same day. Activity limits depend on how the procedure went, whether an intervention was performed, and whether complications were a concern. Clinicians typically provide individualized instructions based on the clinical context.

Q: Does ERCP affect fertility or pregnancy?
ERCP itself is not typically associated with long-term fertility effects, but it involves sedation and fluoroscopy, which raises special considerations in pregnancy. If pregnancy is possible or confirmed, clinicians often adjust imaging and radiation exposure strategies and carefully weigh risks and benefits. Decisions vary by clinician and case.

Q: If a stent is placed, does it last forever?
Stents are not always permanent. Stent function can change over time due to clogging, migration, or tumor progression, and some stents are intended for exchange or removal. The expected durability depends on stent type, anatomy, and the underlying cause of obstruction.